Amylyx gets negative CHMP opinion on marketing authorization of AMX0035

Amylyx announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a negative opinion on the application for conditional marketing authorisation of AMX0035, for the treatment of adults with amyotrophic lateral sclerosis in the European Union. This update follows the company’s May announcement that the CHMP was trending toward a negative opinion.